Citigroup Inc 2seventy Bio, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 36,078 shares of TSVT stock, worth $107,873. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,078

Previous 11,428 215.7%

Holding current value

$107,873

Previous $43,000 295.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.85 - $5.05 $94,902 - $124,482	24,650 Added 215.7%	36,078 $170,000
Q2 2024 Aug 12, 2024	BUY	$3.6 - $5.79 $9,925 - $15,963	2,757 Added 31.8%	11,428 $43,000
Q1 2024 May 10, 2024	BUY	$3.09 - $6.0 $4,103 - $7,968	1,328 Added 18.09%	8,671 $46,000
Q4 2023 Feb 09, 2024	BUY	$1.57 - $4.58 $5,966 - $17,404	3,800 Added 107.25%	7,343 $31,000
Q3 2023 Nov 09, 2023	SELL	$3.14 - $11.2 $257,187 - $917,358	-81,907 Reduced 95.85%	3,543 $13,000
Q2 2023 Aug 10, 2023	SELL	$8.45 - $12.48 $1.5 Million - $2.22 Million	-177,526 Reduced 67.51%	85,450 $864,000
Q1 2023 May 11, 2023	BUY	$9.21 - $14.98 $1.83 Million - $2.97 Million	198,403 Added 307.25%	262,976 $2.68 Million
Q4 2022 Feb 09, 2023	SELL	$8.57 - $17.0 $472,129 - $936,547	-55,091 Reduced 46.04%	64,573 $605,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $17.54 $372,542 - $520,253	29,661 Added 32.96%	119,664 $1.74 Million
Q2 2022 Aug 10, 2022	BUY	$10.55 - $18.81 $554,328 - $988,333	52,543 Added 140.26%	90,003 $1.19 Million
Q1 2022 May 12, 2022	SELL	$11.67 - $26.72 $1.23 Million - $2.81 Million	-105,295 Reduced 73.76%	37,460 $639,000
Q4 2021 Feb 10, 2022	BUY	$13.77 - $42.56 $1.97 Million - $6.08 Million	142,755 New	142,755 $3.66 Million

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $113M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account